NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis
USA - NASDAQ:NBIX - US64125C1099 - Common Stock
152.37 USD
-2.43 (-1.57%)
152.37 USD
0 (0%)
NBIX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties. NBIX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes NBIX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year NBIX was profitable.
NBIX had a positive operating cash flow in the past year.
NBIX had positive earnings in each of the past 5 years.
Each year in the past 5 years NBIX had a positive operating cash flow.
1.2 Ratios
NBIX has a Return On Assets of 10.03%. This is amongst the best in the industry. NBIX outperforms 94.03% of its industry peers.
NBIX has a Return On Equity of 14.25%. This is amongst the best in the industry. NBIX outperforms 94.40% of its industry peers.
NBIX has a Return On Invested Capital of 11.10%. This is amongst the best in the industry. NBIX outperforms 94.59% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NBIX is below the industry average of 15.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
NBIX has a better Profit Margin (15.95%) than 93.66% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 20.64%, NBIX belongs to the top of the industry, outperforming 94.78% of the companies in the same industry.
NBIX's Operating Margin has declined in the last couple of years.
NBIX's Gross Margin of 98.37% is amongst the best of the industry. NBIX outperforms 97.39% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
NBIX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.77 indicates that NBIX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.77, NBIX belongs to the best of the industry, outperforming 81.72% of the companies in the same industry.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.77 |
ROIC/WACC1.27
WACC8.71%
2.3 Liquidity
NBIX has a Current Ratio of 3.38. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.38, NBIX is not doing good in the industry: 61.19% of the companies in the same industry are doing better.
NBIX has a Quick Ratio of 3.27. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.27, NBIX perfoms like the industry average, outperforming 40.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
The Earnings Per Share has been growing by 58.39% on average over the past years. This is a very strong growth
Looking at the last year, NBIX shows a quite strong growth in Revenue. The Revenue has grown by 19.61% in the last year.
Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.05% yearly.
The Revenue is expected to grow by 12.49% on average over the next years. This is quite good.
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.49%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 36.45 indicates a quite expensive valuation of NBIX.
Compared to the rest of the industry, the Price/Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.16% of the companies listed in the same industry.
NBIX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.06.
With a Price/Forward Earnings ratio of 22.09, NBIX is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.54% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.73, NBIX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.45 | ||
| Fwd PE | 22.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 93.28% of the companies listed in the same industry.
NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.48 | ||
| EV/EBITDA | 22.67 |
4.3 Compensation for Growth
NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 36.99% in the coming years.
PEG (NY)0.68
PEG (5Y)0.62
EPS Next 2Y44.8%
EPS Next 3Y36.99%
5. Dividend
5.1 Amount
NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
152.37
-2.43 (-1.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.77%
Inst Owner Change0.54%
Ins Owners1.01%
Ins Owner Change0.61%
Market Cap15.11B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target172.44 (13.17%)
Short Float %4.48%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)1.51%
PT rev (3m)1.58%
EPS NQ rev (1m)3.59%
EPS NQ rev (3m)20.43%
EPS NY rev (1m)11.4%
EPS NY rev (3m)26.67%
Revenue NQ rev (1m)2.62%
Revenue NQ rev (3m)5.15%
Revenue NY rev (1m)2.39%
Revenue NY rev (3m)6.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.45 | ||
| Fwd PE | 22.09 | ||
| P/S | 5.63 | ||
| P/FCF | 25.48 | ||
| P/OCF | 23.73 | ||
| P/B | 5.03 | ||
| P/tB | 5.09 | ||
| EV/EBITDA | 22.67 |
EPS(TTM)4.18
EY2.74%
EPS(NY)6.9
Fwd EY4.53%
FCF(TTM)5.98
FCFY3.92%
OCF(TTM)6.42
OCFY4.21%
SpS27.05
BVpS30.28
TBVpS29.92
PEG (NY)0.68
PEG (5Y)0.62
Graham Number53.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.77 |
F-Score5
WACC8.71%
ROIC/WACC1.27
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.49%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year2.32%
EBIT Next 3Y23.13%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the fundamental rating for NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to NBIX.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.
What is the profitability of NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.
What are the PE and PB ratios of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 36.45 and the Price/Book (PB) ratio is 5.03.